Capital Investment Services of America Inc. Increases Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Capital Investment Services of America Inc. raised its position in Illumina, Inc. (NASDAQ:ILMN) by 2.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 84,617 shares of the life sciences company’s stock after purchasing an additional 1,651 shares during the quarter. Capital Investment Services of America Inc. owned 0.05% of Illumina worth $11,307,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of ILMN. Cetera Investment Advisers increased its position in shares of Illumina by 25.8% during the second quarter. Cetera Investment Advisers now owns 18,384 shares of the life sciences company’s stock worth $1,919,000 after acquiring an additional 3,767 shares during the period. GAMMA Investing LLC grew its stake in Illumina by 31.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,919 shares of the life sciences company’s stock worth $381,000 after purchasing an additional 692 shares in the last quarter. Azzad Asset Management Inc. ADV increased its holdings in Illumina by 8.1% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 4,235 shares of the life sciences company’s stock worth $552,000 after purchasing an additional 317 shares during the period. Diversified Trust Co acquired a new stake in Illumina in the 3rd quarter valued at about $243,000. Finally, Axiom Advisory LLC boosted its stake in shares of Illumina by 3.2% in the 3rd quarter. Axiom Advisory LLC now owns 6,528 shares of the life sciences company’s stock valued at $805,000 after buying an additional 204 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Up 0.4 %

NASDAQ ILMN opened at $124.68 on Thursday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The firm has a 50-day moving average price of $138.19 and a 200 day moving average price of $135.50.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the prior year, the company posted $0.33 earnings per share. Illumina’s quarterly revenue was down 3.5% on a year-over-year basis. On average, equities research analysts predict that Illumina, Inc. will post 4.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Barclays cut their target price on shares of Illumina from $145.00 to $130.00 and set an “equal weight” rating on the stock in a research note on Monday. UBS Group raised their price target on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. increased their price objective on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Royal Bank of Canada upped their price target on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Finally, Stephens raised their price objective on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Eight research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $164.84.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.